Alzheimer’s expert says more clinical trials are needed for controversial Biogen drug

An Alzheimer’s disease expert said Biogen “absolutely” needs to conduct a third clinical trial for aducanumab, its now controversial and recently resurrected Alzheimer’s disease drug candidate.